Literature DB >> 31601577

The Fate of Unruptured Intracranial Vertebrobasilar Dissecting Aneurysm with Brain Stem Compression According to Different Treatment Modalities.

D Y Cho1, B-S Kim2, J H Choi3, Y K Park4, Y S Shin5.   

Abstract

BACKGROUND AND
PURPOSE: Unruptured intracranial vertebrobasilar dissecting aneurysms with brain stem compression are difficult to treat. In the present study, the clinical and radiologic outcomes of unruptured intracranial vertebrobasilar dissecting aneurysms with brain stem compression based on different treatment modalities were evaluated.
MATERIALS AND METHODS: This study included 28 patients with unruptured intracranial vertebrobasilar dissecting aneurysms with brain stem compression treated from January 2009 to December 2017. Treatment methods were observation (n = 6), stent-assisted coil embolization (n = 9), parent artery occlusion (n = 6), and flow diversion (n = 7). The data of baseline characteristics, change of aneurysm size, retreatment rate, stroke occurrence, and alteration of the mRS score were obtained from retrospective chart review.
RESULTS: The initial size of dissecting aneurysms was largest in the flow diversion group (22.5 ± 7.7 mm), followed by parent artery occlusion (20.3 ± 8.4 mm), stent-assisted coil embolization (11.7 ± 2.2 mm), and observation (17.8 ± 5.5 mm; P = .01) groups. The reduction rate of aneurysm size was highest in the parent artery occlusion group (26.7 ± 32.1%), followed by flow diversion (14.1% ± 28.7%), stent-assisted coil embolization (-17.9 ± 30.3%), and observation (-31.5 ± 30.8%; P = .007) groups. Additional treatment was needed in the observation (4/6, 66.7%) and stent-assisted coil embolization (3/9, 33.3%; P = .017) groups. Improvement of the mRS score on follow-up was observed in the flow diversion (6/7, 85.7%) and parent artery occlusion (4/6, 66.7%) groups but not in the stent-assisted coil embolization and observation groups. A worsened mRS score was most common in the observation group (4/6, 66.7%), followed by stent-assisted coil embolization (3/9, 33.3%), parent artery occlusion (2/6, 33.3%), and flow diversion (0/7, 0%) groups.
CONCLUSIONS: When treating intracranial vertebrobasilar dissecting aneurysms with brain stem compression, parent artery occlusion and flow diversion should be considered to reduce aneurysm size and improve the mRS score.
© 2019 by American Journal of Neuroradiology.

Entities:  

Mesh:

Year:  2019        PMID: 31601577      PMCID: PMC6975113          DOI: 10.3174/ajnr.A6252

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  26 in total

1.  Vertebral artery dissection: natural history, clinical features and therapeutic considerations.

Authors:  Kwan-Woong Park; Jong-Sun Park; Sun-Chul Hwang; Soo-Bin Im; Won-Han Shin; Bum-Tae Kim
Journal:  J Korean Neurosurg Soc       Date:  2008-09-20

2.  Strategy for treating unruptured vertebral artery dissecting aneurysms.

Authors:  Yutaka Kai; Toru Nishi; Masaki Watanabe; Motohiro Morioka; Teruyuki Hirano; Shigetoshi Yano; Yuki Ohmori; Takayuki Kawano; Jun-ichiro Hamada; Jun-ichi Kuratsu
Journal:  Neurosurgery       Date:  2011-11       Impact factor: 4.654

3.  Reconstructive Endovascular Treatment of Spontaneous Symptomatic Large or Giant Vertebrobasilar Dissecting Aneurysms: Clinical and Angiographic Outcomes.

Authors:  S Mu; C Li; X Yang; Y Wang; Y Li; C Jiang; Z Wu
Journal:  Clin Neuroradiol       Date:  2014-12-25       Impact factor: 3.649

4.  Coiling of very large or giant cerebral aneurysms: long-term clinical and serial angiographic results.

Authors:  Menno Sluzewski; Tomas Menovsky; Willem Jan van Rooij; Douwe Wijnalda
Journal:  AJNR Am J Neuroradiol       Date:  2003-02       Impact factor: 3.825

5.  Management of intracranial vertebral artery dissections initially presenting without subarachnoid hemorrhage.

Authors:  Isao Naito; Tomoyuki Iwai; Tomio Sasaki
Journal:  Neurosurgery       Date:  2002-10       Impact factor: 4.654

Review 6.  Nonsurgical treatment of unruptured intracranial vertebral artery dissection with serial follow-up angiography.

Authors:  C Kitanaka; J Tanaka; M Kuwahara; A Teraoka; T Sasaki; K Takakura; J ] Tanaki J [corrected to Tanaka
Journal:  J Neurosurg       Date:  1994-04       Impact factor: 5.115

7.  Curative endovascular reconstruction of cerebral aneurysms with the pipeline embolization device: the Buenos Aires experience.

Authors:  Pedro Lylyk; Carlos Miranda; Rosana Ceratto; Angel Ferrario; Esteban Scrivano; Hugh Ramirez Luna; Aaron L Berez; Quang Tran; Peter K Nelson; David Fiorella
Journal:  Neurosurgery       Date:  2009-04       Impact factor: 4.654

8.  Endovascular strategies for vertebrobasilar dissecting aneurysms.

Authors:  S-C Jin; D H Kwon; C-G Choi; J S Ahn; B-D Kwun
Journal:  AJNR Am J Neuroradiol       Date:  2009-05-27       Impact factor: 3.825

9.  Endovascular Treatment of Ruptured Vertebrobasilar Dissecting Aneurysms Using Flow Diversion Embolization Devices: Single-Institution Experience.

Authors:  Waldo R Guerrero; Santiago Ortega-Gutierrez; Minako Hayakawa; Colin P Derdeyn; James D Rossen; David Hasan; Edgar A Samaniego
Journal:  World Neurosurg       Date:  2017-10-05       Impact factor: 2.104

10.  Endovascular occlusion of vertebral arteries in the treatment of unclippable vertebrobasilar aneurysms.

Authors:  A Aymard; Y P Gobin; J E Hodes; S Bien; D Rüfenacht; D Reizine; B George; J J Merland
Journal:  J Neurosurg       Date:  1991-03       Impact factor: 5.115

View more
  2 in total

1.  Conservative Therapy vs. Endovascular Approach for Intracranial Vertebrobasilar Artery Trunk Large Aneurysms: A Prospective Multicenter Cohort Study.

Authors:  Qiaowei Wu; Tianxiao Li; Weijian Jiang; Juha Antero Hernesniemi; Li Li; Yingkun He
Journal:  Oxid Med Cell Longev       Date:  2022-06-20       Impact factor: 7.310

2.  Outcomes of reconstructive endovascular treatment of vertebrobasilar dissecting aneurysms with intramural hematoma.

Authors:  Yisen Zhang; Qichen Peng; Yangyang Zhou; Chao Wang; Longhui Zhang; Xinjian Yang; Shiqing Mu
Journal:  Front Neurol       Date:  2022-08-11       Impact factor: 4.086

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.